Key Highlights
● LIBERTY was a randomized, double-blind Phase 3 trial enrolling 210 healthy adults aged 18 to 49.
● The primary endpoint showed adverse events in 56.5 percent of VYD2311 recipients over six days, versus 91.4 percent for vaccine.
● Over 56 days, adverse events were reported in 60.9 percent of VYD2311 recipients versus 91.4 percent of mRNA Vaccine recipients.
● Invivyd plans a Biologics License Application through the Accelerated Approval Program, with DECLARATION topline data now expected in October.
Invivyd, Inc. (NASDAQ:IVVD) filed a Form 8-K on September 29, 2026, furnishing a press release and a slide presentation that report topline results from LIBERTY, a Phase 3 study of its antibody candidate VYD2311. The company said the study found fewer adverse events among people who received VYD2311 than among people who received an mRNA COVID-19 vaccine, and it outlined how the results fit into its plan to seek approval from the U.S. Food and Drug Administration.
How LIBERTY Was Designed
According to the press release, LIBERTY was a randomized, double-blind Phase 3 trial that enrolled 210 healthy adults aged 18 to 49. Participants were assigned to one of three arms: VYD2311 alone at 250 mg, the mRNA vaccine COMIRNATY alone, or both together. All participants received two intramuscular injections so that the study could remain blinded.
The Safety Results
The primary endpoint measured, over the first six days, the share of subjects with any treatment-emergent adverse event, injection site reaction or hypersensitivity. The release reports that 56.5 percent of VYD2311 recipients had such an event, compared with 91.4 percent of vaccine recipients, with a p-value below 0.0001. That is the same as 56.5 of every 100 recipients versus 91.4 of every 100.
The release reports additional figures. Systemic adverse events occurred in 44.1 percent of the VYD2311 group and 68.1 percent of the vaccine group (p=0.008). Over a longer 56-day window, adverse events were reported in 60.9 percent versus 91.4 percent (p<0.0001). The release says no adverse events related to VYD2311 were higher than Grade 2 and that no hypersensitivity or anaphylaxis was observed. These figures come from the company's own release rather than from a regulatory review.
For the arm that received both products, the release says VYD2311 boosted neutralizing titers by approximately 2.5-fold above vaccine alone, and that no immunologic interference was detected. LIBERTY enrolled healthy adults, and the release describes clinical events collected to date as remaining blinded.
Marc Elia, the company's Chief Executive Officer, is quoted as saying: "We are thrilled to report on this landmark study. LIBERTY has generated the first Phase 3, randomized, blinded, controlled data..."
The Regulatory Plan
Invivyd states that it plans for the DECLARATION and LIBERTY clinical studies to be the basis of a planned Biologics License Application, or BLA, for VYD2311 submitted to the FDA through the Accelerated Approval Program. The release says DECLARATION topline data on safety and immunogenicity to support the submission are now expected in October.
The company also addresses efficacy. It says it intends to pursue Accelerated Approval based on DECLARATION and LIBERTY data while keeping blinded the clinical events collected to date, and that DECLARATION clinical efficacy data are planned to be unblinded after Accelerated Approval, if granted, subject to clinical event accrual. The filing does not state when a BLA would be submitted, and it does not say whether the FDA has agreed to this pathway.
Invivyd held a webcast conference call at 8:30 a.m. ET on September 29, 2026. The 8-K furnishes the press release as Exhibit 99.1 and the presentation as Exhibit 99.2.
DECLARATION Readout Due in October for VYD2311
The next data point named in the filing is the DECLARATION topline safety and immunogenicity readout, which the company now expects in October 2026. That readout is described as supporting the planned BLA submission.
Beyond that, the filing leaves several matters open: the timing of the BLA submission, whether the FDA will accept accelerated approval as the route, and when the blinded efficacy events in DECLARATION would be analyzed, which the company ties to approval and to event accrual.






Please wait processing your request...